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DNA  methylation  and  histone  methylation  are both  involved  in epigenetic  regulation  of gene expression
and  their  dysregulation  can  play an  important  role  in leukemogenesis.  Aberrant  DNA  methylation  has
been reported  to  silence  the  expression  of tumor  suppressor  genes  in  leukemia.  Overexpression  of  the
histone methyltransferase,  EZH2,  a subunit  of  the  polycomb  group  repressive  complex  2 (PRC2),  was
observed  to promote  oncogenesis.  This  is  due  to  aberrant  gene  silencing  by  the  trimethylation  of  histone
H3  lysine  27  (H3K27me3)  by  EZH2.  Since  both  these  epigenetic  silencing  events  are  reversible,  they
are  interesting  targets  for  chemotherapeutic  intervention  by using  an  inhibitor  of  DNA  methylation,
such  as 5-aza-2′-deoxcytidine  (5-AZA-CdR),  and  3-deazaneplanocin-A  (DZNep),  an  inhibitor  of  the  EZH2.
Human  HL-60  and murine  L1210  leukemic  cells  exposed  in  vitro  to  5-AZA-CdR  and  DZNep  in combination
showed  a  synergistic  loss  of clonogenicity  in  a colony  assay  as  compared  to each  agent  alone.  This  positiveistone methylation
ene expression
ouse model
chemotherapeutic  interaction  was  also  observed  in mice  with  L1210  leukemia.  Quantitative  PCR  showed
that the  combination  also  produced  a remarkable  synergistic  activation  of the  tumor  suppressor  genes,
CDKN1A  and  FBXO32.  Microarray  analysis  showed  that 5-AZA-CdR  plus  DZNep  produced  a  synergistic
activation  of  >150  genes.  Our results  indicate  that  5-AZA-CdR  plus  DZNep  can  reactivate  target  genes
that  are  silenced  by  two distinct  epigenetic  mechanisms  leading  to a  loss  of the  proliferative  potential  of
leukemic  cells.
 . Introduction
Epigenetic alterations, such as DNA methylation and histone
odiﬁcations, play an important role in leukemogenesis [1,2].
berrant DNA methylation is a frequent event in patients with
cute leukemia and can be used to predict the outcome of ther-
py [3,4]. The importance of this epigenetic event is illustrated by
he use the inhibitor of DNA methylation, 5-aza-2′-deoxcytidine
5-AZA-CdR, decitabine, dacogen) for the treatment of hemato-
ogical malignancies. 5-AZA-CdR was shown to induce complete
emissions in patients with acute leukemia [5,6] and with myeloid
ysplastic syndrome [7,8]. However, treatment of hematological
alignancies with this epigenetic drug has shown limited efﬁcacyn terms of long-term survival. This may  be due to the development
f drug resistance to 5-AZA-CdR [7–9] and/or the use of a subopti-
al  dose-schedule [10]. These observations provide a rationale to
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search for second agent to use in combination with 5-AZA-CdR to
increase its clinical effectiveness for the treatment of hematological
malignancies.
Polycomb group (PcG) proteins play a key role in the silenc-
ing of genes of differentiation in embryonic stem cells (ESC) and
their dysregulation can lead to cancer [11–13].  Overexpression of
EZH2, a subunit of the PcG repressive complex 2 (PRC2) has been
reported for different types of cancer [14,15].  EZH2 is a histone
methylase that trimethylates histone 3, lysine 27 (H3K27me3), a
gene repressive marker. Dysregulation of this histone modiﬁcation
can lead to epigenetic silencing of genes that promote differenti-
ation and lead to leukemogenesis [11,12]. Since gene silencing by
H3K27me3 is reversible, it is of interest to investigate inhibitors
of histone methylation for the treatment of leukemia. An interest-
ing agent to use for this purpose is 3-deazaneplanocin-A (DZNep),
an inhibitor of the EZH2 [16]. The action of DZNep is due to its
inhibition of S-adenosylhomocysteine hydrolase, which disrupts
methionine metabolism and results in an inhibition of methyl-
Open access under CC BY-NC-ND license.transferases [17]. The inhibition of EZH2 by DZNep was shown to
inhibit colony formation by leukemic cells and reduce the global
level of H3K27me3 [18]. A rationale for selection of DZNep to use
in combination with 5-AZA-CdR for the treatment of leukemia is
1 ia Research 36 (2012) 1049– 1054
t
T
(
P
b
s
o
p
2
2
(
(
s
b
T
(
a
C
t
L
o
t
d
a
2
H
b
s
M
S
t
e
t
t
n

S
m
m
R
(
b
B
2
e
g
l
2
t
i
a
i
b
w
2
5
o
c
3
D
Fig. 1. Clonogenic assay of leukemic cells after sequential treatment with 5-AZA-
CdR (5AZA) and DZNep (DZN). (A) HL-60 cells were treated with 100 nM 5AZA and/or
at  24 h 1000 nM DZN was added to the medium. At 48 h cells were placed in soft agar
medium for colony assay. (B) L1210 cells were treated with 100 nM 5AZA and/or
at  12 h 100 nM DZN was added to the medium. At 24 h cells were placed in soft050 R.L. Momparler et al. / Leukem
hat there exists a “cross-talk” between EZH2 and DNA methylation.
his is due to the recruitment by EZH2 of DNA methyltransferases
DNMTs) to the promoter region of PcG target genes [19,20]. These
cG target genes in embryonic stem cells are >10-fold more likely to
e hypermethylated in cancers [13]. In this study we have observed
ynergistic antileukemic action between 5-AZA-CdR and DZNep
n leukemic cells. Preliminary results of this study were reported
reviously [21].
. Materials and methods
.1. Cells and drug treatment
5-AZA-CdR and DZNep were dissolved in sterile phosphate buffer saline pH 7.4
PBS) solution and stored at −70 ◦C. The mouse lymphoid leukemia cell line L1210
doubling time 10–12 h) was  maintained in RPMI-1640 medium with 10% fetal calf
erum and 10 M of 2-mercaptoethanol. HL-60 human myeloid leukemic cells (dou-
ling  time 18 h) were maintained in RPMI-1640 medium with 10% fetal calf serum.
he cells were treated with 100 nM 5-AZA-CdR. At 24 h (HL-60 cells) and at 12 h
L1210 cells), 1000 nM DZNep was added to the medium. At 48 h (HL-60 cells) and
t  24 h (L1210 cells), a cell count was performed using the Beckman Model Z Coulter
ounter. For clonogenic assay 150 cells were placed in 0.36% soft agar medium con-
aining 20% serum for HL-60 cells or 10% serum plus 6 M 2-mercaptoethanol for
1210 cells. The number of colonies (>500 cells) was counted after 10 and 18 days
f incubation for L1210 and HL-60 cells, respectively. The cloning efﬁciency was  in
he  range of 60–75%. For analysis of gene expression in HL-60 cells, at the end of
rug treatment (48 h), the cells were centrifuged, suspended in drug-free medium
nd  RNA was isolated at 72 h as described below.
.2. Analysis of gene expression
For quantitative PCR analysis total RNA was reversed transcribed using the
igh Capacity cDNA Reverse Transcription Kit with random primers as described
y  the manufacture (Applied Biosystems). The reaction mixture contained cDNA,
peciﬁc primers for the target genes, Sybr green and TaqMan Fast Universal PCR
aster Mix  (Applied Biosystems). The ABI PRISM 7900HT Sequence Detection
ystem (Applied Biosystems) was used to detect the ampliﬁcation level. All reac-
ions were run in triplicate and the average Cts were used for quantitation. The
ndogenous control was the TATA-binding protein (TBP) gene. The relative quan-
iﬁcation of the target genes was determined using the CT method. Brieﬂy,
he Ct (threshold cycle) values of the target gene were normalized to the endoge-
ous control TPB gene (CT = Cttarget −Ctcontrol) and compared with a calibrator:
CT  = Ctsample − Ctcalibrator. Relative expression (RQ) was calculated using the
equence Detection System (SDS) 2.2.2 software (Applied Biosystems) and the for-
ula: RQ = 2−CT.
For microarray analysis of gene expression, at 24 h after the end of drug treat-
ent total RNA was isolated from HL-60 cells using the RNAeasy Mini kit (Qiagen).
everse transcription was  performed using the Total Prep RNA Ampliﬁcation kit
Ambion). The cDNA synthesis and in vitro transcription ampliﬁcation were followed
y  hybridization microarray hybridization using the Human WG-6 v.3.0 Expression
eadChip kit (Illumina). The beads contain thousands of 50-mer probes speciﬁc for
9,346 genes. The BeadChips were imaged using Illumina’s BeadArray or iScan read-
rs. Data analysis was performed using SAS9.2 AND JMP  Genomics 5.0. The data on
ene expression from the arrays were normalized by median centering and average
inkage hierarchical clustering performed using Cluster and Treeview software.
.3.  Mouse model of leukemia
Chemotherapy was  performed on CD2F1 male mice (Charles River). The insti-
utional animal committee approved the experimental protocols. The mice were
njected i.v. with 104 L1210 cells on day 0. On day 1 5-AZA-CdR (2 mg/kg) was
dministered by continuous 12 h i.v. infusion into the lateral tail vein using Harvard
nfusion pump. DZNep (2.5 or 3.75 mg/kg) was administered 1 and 6 h post-infusion
y  i.p. injection. The survival time and weight loss of each group of leukemic mice
ere monitored and the increase in life span (ILS) calculated.
.4. Statistical analysis
Data were analyzed for statistical signiﬁcance using GraphPad Prism version
.0d for Mac OS 10 from GraphPad Software (www.graphpad.com). For comparison
f  different groups the data were analyzed using one-way ANOVA Turkey’s multiple
omparison or t test. A value p < 0.05 was taken to indicate statistical signiﬁcance.. Results
To evaluate the in vitro antineoplastic action of 5-AZA-CdR and
ZNep we incubated these agents with the leukemic cells andagar medium for colony assay. The results are expressed as mean ± SEM, n = 3. Data
analysis: for both (A) and (B), 5AZA or DZN vs 5AZA + DZN, p < 0.05 (one way  ANOVA).
determined their loss of clonogenicity using a soft agar colony
assay. Incubation of human HL-60 leukemic cells with 5-AZA-CdR
100 nM for 24 h and DZNep 1000 nM for 24 produced a 38.0 ± 5.4
(mean ± SEM) and 35.0 ± 6.0% loss of clonogenicity, respectively
(Fig. 1A). Sequential treatment of 5-AZA-CdR for 24 h followed
by the addition of DZNep for 24 h resulted in 95.0 ± 0.7% loss of
clonogenicity. For the murine L1210 leukemic cells 5-AZA-CdR
100 nM and DZNep 100 nM alone for 12 h produced a 51.7 ± 3.8
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Table  1
Antineoplastic activity of 5-aza-2′-deoxycytidine (5-AZA-CdR) and 3-deazaneplanocin A (DZNep) in mice with L1210 leukemia.
Drug(s) Dose (mg/kg) Infusion time Survival (days) % increase life span (ILS)
Experiment #1
Control (no drug) 0 7.7 ± 0.2* 0%
5-AZA-CdR 2 mg/kg (i.v.) 12 h 13.6 ± 0.5 76.6%**
DZNep 5 mg/kg (i.p.) 9.4 ± 0.3 22.1%
5-AZA-CdR + DZNep 2 mg/kg + 5 mg/kg 12 h 15.9 ± 1.5 106.5%**
Experiment #2
Control (no drug) 0 6.9 ± 0.4* 0%
5-AZA-CdR 2 mg/kg (i.v.) 12 h 12.5 ± 0.3 81.2%**
DZNep 7.5 mg/kg (i.p.) 9.1 ± 0.2 31.9%
5-AZA-CdR + DZNep 2 mg/kg + 7.5 mg/kg 12 h 14.3 ± 1.1 107.2%**
CD2F1 male mice were injected i.v. with 10,000 L1210 leukemic cells on day 0. On day 1 the mice received n 12 h i.v. infusion of 5-AZA-CdR (2 mg/kg). DZNep 2.5 mg/kg
(Experiment #1) or 3.75 mg/kg (Experiment #2) was  injected i.p. at 1 h and 6 h after end of infusion giving a total dose of 5.0 and 7.5 mg/kg, respectively. There were 5 mice
per  group. Survival time was determined.
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b* Mean ± SEM.
** 5-AZA-CdR vs 5-AZA-CdR + DZNep (p < 0.05; t test).
nd 18.3 ± 1.5% loss of clonogenicity, respectively (Fig. 1B). Sequen-
ial exposure of 5-AZA-CdR for 12 h followed by DZNep for 12 h
roduced 87.7 ± 1.2% loss of clonogenicity. For both leukemic cell
ines the interaction between these two epigenetic agents was
ynergistic according to the method of Valeriote and Lin [22,23],
hich deﬁnes when: SFdrugA+drugD < SFdrugA × SFdrugD the interac-
ion is synergistic, where SF = survival fraction.
In order to determine if the combination could produce a
omplete eradication of the proliferative potential of the HL-60
eukemic cells we increased the concentration of 5-AZA-CdR from
00 to 200 nM followed by the addition of DZNep as described
bove (Supplementary data, Table 1S).  Under these conditions a
omplete loss of clonogenicity was observed by the combination
s shown by the absence of colonies in the tubes containing the
ombination.
We next determined if this positive interaction of these epi-
enetic agents was also observable in vivo using the L1210 mouse
odel of leukemia (Table 1). Mice were injected i.v. with 104 L1210
eukemic cells on day 0 and administered sequentially 2 mg/kg
-AZA-CdR as 12 h i.v. infusion on day 1 and/or injected i.p. at 1
nd 6 h post-infusion DZNep 2.5 mg/kg (Experiment #1) or DZNep
.75 mg/kg (Experiment #2). For Experiment #1: the untreated
ice died from leukemia at 7.7 ± 0.2 days (mean ± SEM). Mice
reated with 5-AZA-CdR or DZNep alone died at 13.6 ± 0.5 and
.4 ± 0.3 days, respectively, which corresponds to a 76.6 and 22.1%
ncreased the life span (ILS) of the leukemic mice, respectively.
he combination produced 106.5% ILS. For Experiment #2: the
ntreated mice died from leukemia at 6.9 ± 0.4 days. Mice treated
ith 5-AZA-CdR or DZNep alone died at 12.5 ± 0.3 and 9.1 ± 0.2
ays, respectively, which corresponds to a 81.2 and 31.9% ILS,
espectively. The combination produced 107.2% ILS. The differences
n survival produced by 5-AZA-CdR alone compared to 5-AZA-CdR
lus DZNep was statistically signiﬁcant (p < 0.05, t test).
We then investigated if 5-AZA-CdR and DZNep in combination
ould activate silent tumor suppressor genes in HL-60 leukemic
ells using quantitative PCR. The relative expression of the genes
as compared to the endogenous control gene, TBP. We  observed
hat the combination produced a synergistic activation of CDKN1A
nd FBXO32 and (Fig. 2A and C). The activation of CDKN1B by
he combination appeared to be only additive (Fig. 2B). The dif-
erence in the activation of CDKN1A and FBXO32 by 5-AZA-CdR as
ompared to 5-AZA-CdR + DZNep was signiﬁcant (p < 0.05, one way
NOVA). Since the MYC  oncogene is ampliﬁed in HL-60 leukemic
ells [24], we  investigated the action of these epigenetic agents
n the expression of this gene (Fig. 2D). 5-AZA-CdR alone, but not
ZNep, decreased the expression of MYC. The combination showed
 greater reduction in the expression of MYC  than 5-AZA-CdR alone,
ut the difference was n.s.In order to obtain a global assessment of gene expression
produced by 5-AZA-CdR and DZNep, we performed an Illumina
microarray analysis. 5-AZA-CdR and DZNep alone showed a signif-
icant change in the expression of 571 and 426 genes, respectively
(Fig. 3a). The combination of these agents changed the expression
of 1574 genes, indicating a synergistic interaction. The Venn dia-
gram shows that there was  some overlap in the genes activated
by 5-AZA-CdR or DZNep (Fig. 3b). The cluster diagram shows a
remarkable change in global gene expression in leukemic cells pro-
duced by 5-AZA-CdR and DZNep in combination as compared to
each agent alone (Fig. 3c). Further analysis of the microarray data
showed that the combination produced a synergistic activation of
expression of >150 genes and synergistic suppression of expression
of 20 genes (Supplementary data, Table 2S). These data suggest that
many genes in cells are silenced by DNA methylation in association
with H3K27 methylation. Sun et al. [25] and Miranda et al. [26]
reported that DZNep and 5-AZA-CdR increased the expression of
different cohorts of genes in tumor cells. Tan et al. [16] observed
that DZNep increased the expression of 140 genes in tumor cells,
including FBXO31.
4. Discussion
Epigenetic therapy of in patients with hematological malig-
nancies using 5-AZA-CdR has produced interesting responses, but
few long-term survivors [5,7,8].  A second agent that enhances the
antileukemic action of 5-AZA-CdR has the potential to increase
the effectiveness of this epigenetic therapy. An interesting epige-
netic agent to investigate for this purpose is DZNep. In preclinical
studies DZNep shows both in vitro and in vivo antileukemic activ-
ity [18]. DZNep inhibits histone methylation, reducing the level of
H3K27me3 in leukemic cells, which leads to the activation of genes
that suppress leukemogenesis [16,18,26].
Our data showed that sequential treatment of 5-AZA-CdR fol-
lowed by DZNep showed a synergistic interaction with respect to
its antileukemic activity as shown by a loss of clonogenicity for both
human myeloid and murine lymphoid leukemic cell lines (Fig. 1).
It was also possible to demonstrate that by increasing the concen-
tration of 5-AZA-CdR, the combination could produce a complete
eradication of the proliferative potential of the HL-60 leukemic
cells (Table 1S). The data obtained in mice with L1210 leukemia
are in accord with the in vitro data where the combination showed
a greater increase in survival time than the 5-AZA-CdR treatment
alone (Table 1).Of interest is the molecular mechanism responsible for the inter-
esting interaction between these two  different epigenetic agents.
We observed that 5-AZA-CdR in combination with DZNep produced
a synergistic activation of the tumor suppressor genes, CDKN1A
1052 R.L. Momparler et al. / Leukemia Research 36 (2012) 1049– 1054
Fig. 2. Quantitative PCR analysis of gene expression in HL-60 leukemic cells following sequential treatment with 5-AZA-CdR (5AZA) and/or DZNep (DZN). Leukemic cells
were  treated with 100 nM 5AZA and 1000 nM DZN was  added to the medium at 24 h. At 48 h the cells were placed in drug-free medium. At 72 h RNA was isolated for RT-PCR
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Analysis as described in Section 2. The results are expressed as mean ± SEM, n = 3. D
one  way ANOVA). For (D) MYC, 5AZA vs control, p < 0.05; 5AZA vs 5AZA + DZN, n.s.
nd FBXO32 (Fig. 2). FBXO32 is a putative tumor suppressor gene
hat can play a role in the induction of apoptosis [16]. Promoter
NA hypermethylation was reported to silence the expression of
BXO32 in tumor cells [27].One possible explanation for this positive interaction between
hese epigenetic agents is that each agent changes the expression
f different cohorts of genes leading to a potent antileukemic effect.
lso to be taken under consideration is the activation of target genesnalysis: for (A) CDKN1A, (B) CDKN1B and (C) 5AZA or DZN vs 5AZA + DZN, p < 0.05
ay  ANOVA).
that contain two  gene suppressive marks: DNA methylation and
H3K27me3 methylation. Activation of these target genes by either
5-AZA-CdR or DZNep alone can be only moderate, but in com-
bination a synergistic activation occurs. This is clearly illustrated
in Fig. 2 that shows the synergistic activation of the tumor sup-
pressor genes: CDKN1A and FBXO31 (Fig. 2). We also investigated
global gene expression in the leukemic cells after treatment with
these epigenetic agents using Illumina microarray analysis. The
R.L. Momparler et al. / Leukemia Research 36 (2012) 1049– 1054 1053
Fig. 3. Analysis of gene expression data in HL-60 leukemic cells after sequential treatment with 5-AZA-CdR (A), DZNep (D) or combination (A + D). The leukemic cells were
treated  with the drugs as indicated in Fig. 2. (a) Numbers of genes differentially expressed at 1% False Discovery Rate (Benjamini and Hocheber’s FDR). (b) Venn diagram
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ach  row represents a gene differentially expressed in at least one contrast. Intensit
elatively low expression. Gene expression data were generated using Illumina Hum
ierarchical cluster diagram shows signiﬁcant changes in gene
xpression by the combination of 5-AZA-CdR and DZNep as com-
ared to each agent alone (Fig. 3). It is possible that the synergistic
ntileukemic action of the combination is related to the modi-
cation of expression of a larger number of genes as compared
o gene changes by single agent treatment. Our microarray data
howed the synergistic activation of >150 genes by this combi-
ation (Supplementary data, Table 1S). In tumor cells 5-AZA-CdR
nd DZNep alone were reported to activate the expression of
ifferent cohorts of genes [25,26],  which is in accord with our
ata. Breast cancer cells following simultaneous treatment of
-AZA-CdR and DZNep showed a synergistic activation of sev-
ral genes, including a cohort of genes of GAGE cancer/testis
ntigen family [25]. Of interest is the down regulation by 5-
ZA-CdR and the combination of the MYC, an oncogene that is
mpliﬁed in HL-60 cells [24]. We  also observed that the combi-
ation also show a synergistic down regulation of some genes
Table 2S).  The mechanism for gene repression by these epige-
etic agents is not clear and may  be due to activation of repressor
enes.
The intensity of gene activation by 5-AZA-CdR in combination
ith DZNep may  also be important with respect to the eradica-
ion of the “self-renewal” potential of leukemic stem cells. In this
egard, the silencing of genes that suppress leukemogenesis due
o the presence of two  suppressor markers, such as DNA and his-
one methylation, provides a “double lock” mechanism, that can be
eactivated by a combination of epigenetic agents. The synergistic
ctivation of these target genes by 5-AZA-CdR plus DZNep supports. (c) Two-way hierarchical clustering of expression before and after drug treatment.
d indicates relatively high expression relative to the sample mean, intensity of blue
G-6 v.3.0 Bead-array system and analyzed using JMP  Genomics v5.0.
this hypothesis and takes place in both leukemic and tumors cells.
These data are in accord with observation that PcG target genes
show a high frequency of DNA methylation in cancer due to the
“cross-talk” between these two events [13,19,20].  Abnormal gene
silencing by epigenetic events can lead to cancer, whereas their
reversal by inhibitors of DNA and histone methylation can pro-
duce a potent antineoplastic effect. However, the precise molecular
mechanism by which these epigenetic agents eradicate the pro-
liferative potential of leukemic cells still remains to be clariﬁed.
This interesting combination of epigenetic agents merits further
investigation for its chemotherapeutic potential for the treatment
of leukemia and as a tool to investigate the role of epigenetic alter-
ations during leukemogenesis.
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